Teva Pharmaceuticals Company IP News and Updates

Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted...

  Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in...

In August, our much-anticipated fourth annual ANDA Litigation Intelligence Report made its entrance into the world of pharmaceutical litigation. This...

    In a groundbreaking legal development, Eli Lilly has secured a remarkable victory in a high-stakes patent battle that...

Last August, we published our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape and focused...

Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the...

CASE OF THE WEEK GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., Appeal No. 2018-1976, -2023 (Fed. Cir. Oct. 2, 2020)...

GLAXOSMITHKLINE LLC v. TEVA PHARMACEUTICALS USA, INC. [OPINION] – PRECEDENTIAL Before Prost, Newman, and Moore.  Appeal from the U.S. District...

In Galderma Labs. v. Teva Pharm. USA, Inc., Appeal Nos. 2019-2396 and 2020-1213 (Fed. Cir,. January 29, 2020), a Fed....

Last year, in a lengthy split decision, a Fed. Cir. panel affirmed the district court’s ruling that four “add-on” patents...